IL158600A - Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent - Google Patents

Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent

Info

Publication number
IL158600A
IL158600A IL158600A IL15860003A IL158600A IL 158600 A IL158600 A IL 158600A IL 158600 A IL158600 A IL 158600A IL 15860003 A IL15860003 A IL 15860003A IL 158600 A IL158600 A IL 158600A
Authority
IL
Israel
Prior art keywords
acetylcholinesterase
inflammatory agent
antisense deoxyoligonucleotide
deoxyoligonucleotide
antisense
Prior art date
Application number
IL158600A
Other languages
English (en)
Hebrew (he)
Other versions
IL158600A0 (en
Inventor
Hermona Soreq
Raz Yirmiya
Original Assignee
Hermona Soreq
Yissum Res Dev Co
Raz Yirmiya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hermona Soreq, Yissum Res Dev Co, Raz Yirmiya filed Critical Hermona Soreq
Priority to IL158600A priority Critical patent/IL158600A/en
Publication of IL158600A0 publication Critical patent/IL158600A0/xx
Priority to EP04791840A priority patent/EP1682072A4/en
Priority to EP13153748.2A priority patent/EP2599489A1/en
Priority to PCT/IL2004/000978 priority patent/WO2005039480A2/en
Priority to CA002543305A priority patent/CA2543305A1/en
Priority to JP2006537550A priority patent/JP4753088B2/ja
Priority to US11/187,719 priority patent/US20060069051A1/en
Priority to US11/788,321 priority patent/US20090005331A1/en
Priority to US13/351,171 priority patent/US20130018081A1/en
Priority to US13/899,922 priority patent/US8722876B2/en
Publication of IL158600A publication Critical patent/IL158600A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL158600A 2003-10-26 2003-10-26 Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent IL158600A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL158600A IL158600A (en) 2003-10-26 2003-10-26 Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
JP2006537550A JP4753088B2 (ja) 2003-10-26 2004-10-26 抗炎症薬としてのＡＣｈＥアンチセンスデオキシオリゴヌクレオチド
CA002543305A CA2543305A1 (en) 2003-10-26 2004-10-26 Ache antisense deoxyoligonucleotide as an anti-inflammatory agent
EP13153748.2A EP2599489A1 (en) 2003-10-26 2004-10-26 AChE antisense deoxyoligonucleotide as an anti-inflammatory agent
PCT/IL2004/000978 WO2005039480A2 (en) 2003-10-26 2004-10-26 AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
EP04791840A EP1682072A4 (en) 2003-10-26 2004-10-26 ACHE ANTISENSE DESOXYOLIGONUCLEOTIDE AS ANTI-INFLAMMATORY AGENT
US11/187,719 US20060069051A1 (en) 2003-10-26 2005-07-21 AChE antisense oligonucleotide as an anti-inflammatory agent
US11/788,321 US20090005331A1 (en) 2003-10-26 2007-04-18 AChE antisense oligonucleotide as an anti-inflammatory agent
US13/351,171 US20130018081A1 (en) 2003-10-26 2012-01-16 AChE ANTISENSE OLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
US13/899,922 US8722876B2 (en) 2003-10-26 2013-05-22 Antisense oligonucleotides against AChE in the treatment of gastrointestinal inflammation disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL158600A IL158600A (en) 2003-10-26 2003-10-26 Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent

Publications (2)

Publication Number Publication Date
IL158600A0 IL158600A0 (en) 2004-05-12
IL158600A true IL158600A (en) 2015-07-30

Family

ID=34044237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL158600A IL158600A (en) 2003-10-26 2003-10-26 Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent

Country Status (6)

Country Link
US (3) US20060069051A1 (enExample)
EP (2) EP1682072A4 (enExample)
JP (1) JP4753088B2 (enExample)
CA (1) CA2543305A1 (enExample)
IL (1) IL158600A (enExample)
WO (1) WO2005039480A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007399A2 (en) * 2006-04-10 2008-12-31 Ester Neurosciences Ltd. Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
US20110136897A1 (en) * 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20220102008A1 (en) * 2020-09-30 2022-03-31 Genentech, Inc. Methods and systems for placebo response modeling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AU727611B2 (en) * 1996-12-12 2000-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
AU8742198A (en) * 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
EP2007399A2 (en) * 2006-04-10 2008-12-31 Ester Neurosciences Ltd. Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases

Also Published As

Publication number Publication date
IL158600A0 (en) 2004-05-12
WO2005039480A3 (en) 2006-08-03
WO2005039480A8 (en) 2006-06-15
EP1682072A4 (en) 2010-10-13
CA2543305A1 (en) 2005-05-06
US20130310441A1 (en) 2013-11-21
JP2007509186A (ja) 2007-04-12
EP1682072A2 (en) 2006-07-26
US20060069051A1 (en) 2006-03-30
US20090005331A1 (en) 2009-01-01
US8722876B2 (en) 2014-05-13
JP4753088B2 (ja) 2011-08-17
WO2005039480A2 (en) 2005-05-06
EP2599489A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
IL162642A0 (en) Formulations
GB0312309D0 (en) Targeted liposome
EP1676582A4 (en) AGENT CONTROLLING CORONAVIRUS
ZA200602339B (en) HRT Formulations
PL1670440T3 (pl) Preparaty HRT
GB0323701D0 (en) Formulations
GB0305989D0 (en) Agent
IL175857A0 (en) Anti-inflammatory agents
IL158600A (en) Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
EP1595526A4 (en) PREPARATION OF CAPILLARY COLOR
GB0307765D0 (en) Tissue-adhesive formulations
GB2398992B (en) Underwear
GB0318257D0 (en) Nucleating agent
EP1709976A4 (en) EMT-INDUCING MEDIUM
GB2419593B (en) Novel fragrance derivatives
GB0318014D0 (en) Anti-inflammatory agent
GB0327775D0 (en) Anti-inflammatory agents
GB0311576D0 (en) Anti-inflammatory agents
AU154758S (en) Napkin
EG23731A (en) Tissue engineering
GB0319551D0 (en) Formulations
GB0319549D0 (en) Formulations
GB0318871D0 (en) Tissue-adhesive formulations
GB0318503D0 (en) Formulations
HU0302272D0 (en) Perfumed litterbag

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees